A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs RSLV 132 (Primary)
- Indications Sjogren's syndrome
- Focus Pharmacodynamics
- Acronyms RSLV-132
- Sponsors Resolve Therapeutics
- 09 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Jun 2018 Planned End Date changed from 15 Jan 2018 to 15 Jan 2019.
- 01 Jun 2018 Planned primary completion date changed from 15 Nov 2017 to 15 Oct 2018.